Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rhenium 188 P 2045 (Primary)
Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Andarix Pharmaceuticals; Bayer; Bayer HealthCare Pharmaceuticals Inc.

Most Recent Events

31 Oct 2022 Status changed to recruiting.
31 Oct 2022 Planned End Date changed from 1 Apr 2020 to 20 Apr 2025.
29 May 2009 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight